These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9717816

  • 1. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.
    Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
    [Abstract] [Full Text] [Related]

  • 2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 3. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
    Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT.
    Clin Cancer Res; 2001 Aug 15; 7(8):2237-45. PubMed ID: 11489797
    [Abstract] [Full Text] [Related]

  • 4. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
    Delsite R, Djakiew D.
    J Androl; 1996 Aug 15; 17(5):481-90. PubMed ID: 8957691
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M.
    Int J Oncol; 2007 Jan 15; 30(1):193-200. PubMed ID: 17143529
    [Abstract] [Full Text] [Related]

  • 6. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
    Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT.
    Cancer Res; 2002 Feb 15; 62(4):986-9. PubMed ID: 11861369
    [Abstract] [Full Text] [Related]

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 8. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA.
    Clin Cancer Res; 1999 Aug 15; 5(8):2205-12. PubMed ID: 10473107
    [Abstract] [Full Text] [Related]

  • 9. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
    Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A.
    Cancer Res; 2001 Jul 15; 61(14):5432-40. PubMed ID: 11454688
    [Abstract] [Full Text] [Related]

  • 10. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.
    Cancer Res; 2000 Sep 15; 60(18):5165-70. PubMed ID: 11016644
    [Abstract] [Full Text] [Related]

  • 11. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
    Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.
    Int J Cancer; 1997 Aug 07; 72(4):673-9. PubMed ID: 9259409
    [Abstract] [Full Text] [Related]

  • 12. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC.
    Carcinogenesis; 2004 Apr 07; 25(4):517-25. PubMed ID: 14688027
    [Abstract] [Full Text] [Related]

  • 13. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
    Vukanovic J, Isaacs JT.
    Cancer Res; 1995 Aug 15; 55(16):3517-20. PubMed ID: 7543015
    [Abstract] [Full Text] [Related]

  • 14. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ.
    Clin Cancer Res; 2000 Mar 15; 6(3):1190-7. PubMed ID: 10741751
    [Abstract] [Full Text] [Related]

  • 15. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.
    Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ.
    Prostate; 2004 Mar 01; 58(4):382-93. PubMed ID: 14968439
    [Abstract] [Full Text] [Related]

  • 16. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 01; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R.
    Prostate; 2007 Aug 01; 67(11):1182-93. PubMed ID: 17520666
    [Abstract] [Full Text] [Related]

  • 18. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
    Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S.
    Cancer Res; 2004 Jul 15; 64(14):4875-86. PubMed ID: 15256458
    [Abstract] [Full Text] [Related]

  • 19. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R.
    Clin Cancer Res; 2002 Nov 15; 8(11):3512-9. PubMed ID: 12429642
    [Abstract] [Full Text] [Related]

  • 20. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.